Overactive bladder: Targeting prostaglandins in sensory pathways

Drug Discovery Today: Therapeutic Strategies

Volumn 2, Issue 1, 2005, Pages 7-13

  Wibberley, Alexandra ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [3 (4 CHLORO 2 METHYLPHENYLSULFONYLAMINOMETHYL)BICYCLO[2.2.2]OCTAN 2 YL] 5 HEXENOIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DELTA15 PROSTAGLANDIN J2; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; INDOMETACIN; KETOPROFEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN; PROSTAGLANDIN D RECEPTOR BLOCKING AGENT; PROSTAGLANDIN D RECEPTOR STIMULATING AGENT; PROSTAGLANDIN E RECEPTOR BLOCKING AGENT; PROSTAGLANDIN F RECEPTOR BLOCKING AGENT; PROSTAGLANDIN I2 RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR AFFECTING AGENT; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; ZD 6416;

ARTICLE; BLADDER CAPACITY; CARDIOVASCULAR DISEASE; DIGESTIVE SYSTEM ULCER; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HEARTBURN; HUMAN; INDIGESTION; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; OVERACTIVE BLADDER; PROSTAGLANDIN SYNTHESIS INHIBITION; URGE INCONTINENCE; URINARY FREQUENCY; URINARY URGENCY; URODYNAMICS;

EID: 21644468515     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2005.05.022     Document Type: Review

References (40)

1. E.S. Rovner A.J. Wein Incidence and prevelance of overactive bladder Curr. Urol. Rep. 3 2002 434-438
2. W.D. Steers Pathophysiology of overactive bladder and urge urinary incontinence Rev. Urol. 4 2002 S7-S18
3. D.P. Mikhailidis et al. Urinary bladder prostanoids - their synthesis, function and possible role in the pathogenesis and treatment of disease J. Urol. 137 1987 577-582
4. C.A. Maggi Prostanoids as local modulators of reflex micturition Pharm. Res. 25 1992 13-20
5. A. Bergman et al. The role of prostaglandins in detrusor instability Am. J. Obstet. Gynecol. 165 1991 1833-1836
6. H. Vanegas H.G. Schaible Prostaglandins and cyclooxygenases in the spinal cord Prog. Neurobiol. 64 2001 327-363
7. A.N. Hata R.M. Breyer Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation Pharm. Ther. 103 2004 147-166
8. H. Takagi-Matsumoto et al. Effects of NSAIDs on bladder function in normal and cystitis rats: A comparison study of aspirin, indomethacin, and ketoprofen J. Pharmacol. Sci. 95 2004 458-465
9. I.M. Khalaf et al. The effect of exogenous prostaglandins F2 alpha and E2 and indomethacin on micturition Br. J. Urol. 53 1981 21-28
10. K.P.J. Delaere et al. The use of indomethacin in the treatment of idiopathic bladder instability Urol. Int. 36 1981 124-127
11. L.D. Cardozo S.L. Stanton A comparison between bromocriptine and indomethacin in the treatment of detrusor instability J. Urol. 123 1980 399-401
12. T.K. Chaudhuri et al. Double-blind placebo controlled randomized trial of indomethacin on urodynamic values measured by radionuclide imaging Clin. Autism Res. 3 1993 37-40
13. J.M. Malinovsky et al. The urodynamic effects of intravenous opioids and ketoprofen in humans Anesth. Analg. 87 1998 456-461
14. J. Palmer Report of a double-blind crossover study of flurbiprofen and placebo in detrusor instability J. Int. Med. Res. 11 1983 11-17
15. L.D. Cardozo et al. Evaluation of flurbiprofen in detrusor instability Br. Med. J. 280 1980 281-282
16. R. Micklewright et al. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors Aliment Pharmacol. Ther. 17 2003 321-332
17. M. Sprem et al. Intravesically administered ketoprofen in treatment of detrusor instability: Cross-over study Croat. Med. J. 41 2000 423-427
18. A. Lecci et al. Pharmacological evaluation of the role of cyclooxygenase isoenzymes on the micturition reflex following experimental cystitis in rats Br. J. Pharmacol. 130 2000 331-338
19. V.Y. Hu et al. COX-2 and prostanoid expression in micturition pathways after cyclophosphamide-induced cystitis in the rat Am. J. Physiol. 284 2003 R574-R585
20. J.M. Park et al. Obstruction stimulates COX-2 expression in bladder smooth muscle cells via increased mechanical stretch Am. J. Physiol. 276 1999 F129-F136
21. Leonardi et al. [Recordati] (2002) Use of selective COX-2 inhibitors for the treatment of urinary incontinence. US6,440,963B1
22. P.A. Howard P. Delafontaine Nonsteroidal anti-Inflammatory drugs and cardiovascular risk J. Am. Coll. Cardiol. 43 2004 519-525
23. M. Michaelis et al. Silent afferents: A separate class of primary afferents? Clin. Exp. Pharm. Phys. 23 1996 99-105
24. Y. Zhang et al. Genomic structure and genitourinary expression of mouse cystolic prostaglandin E2 synthase gene Biochim. Biophys. Acta 1634 2003 15-23
25. P.J. Jakobsson et al. Identification of human prostaglandin E synthase: A microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target Proc. Natl. Acad. Sci. 96 1999 7220-7225
26. M.D. Breyer et al. Prostanoid receptors and the urogenital tract Curr. Opin. Invest. Drugs 4 2003 1343-1353
27. A. Schroder et al. Detrusor responses to prostaglandin E2 and bladder outlet obstruction in wild-type and EP1 receptor knockout mice J. Urol. 172 2004 1166-1170
28. M. Ikeda et al. EP1 receptor antagonist inhibits the effects of prostaglandin on the bladder afferent activity in the rats with irritative symptoms J. Urol. 171 2004 1747
29. A. Miura et al. Effect of prostaglandins on parasympathetic neurons in the rat lumbosacral spinal cord Neuroreport 13 2002 1557-1562
30. S. Sarkar et al. The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans Gastroenterology 124 2003 18-25
31. K. Takeuchi et al. Adaptive gastric cytoprotection is mediated by prostaglandin EP1 receptors: A study using rats and knockout mice J. Pharm. Exp. Ther. 297 2001 1160-1165
32. Giblin, G.M.P. et al. [GlaxoSmithKline] (2001) Benzo (F) Isoindol derivatives and their use as EP4 receptor ligands. WO/50033A1
33. J.W. Regan EP2 and EP4 prostanoid receptor signaling Life Sci. 74 2003 143-153
34. Keitz, P.F. et al. [Roche] (2004) Substituted arylamides as IP antagonists. US 2004/0220247A1
35. Murata, T. et al. [Bayer] (2004) Bis (hetero) aryl carboxamide derivatives for use as PGI2 antagonists. WO 2004/069805A1
36. T. Muratani et al. Functional characterization of prostaglandin F2alpha receptor in the spinal cord for tactile pain (allodynia) J. Neurochem. 86 2003 374-382
37. D.H. Wright et al. A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor Eur. J. Pharmacol. 377 1999 101-115
38. T. Minami et al. Prostaglandin D2 inhibits prostaglandin E2-induced allodynia in conscious mice J. Pharmacol. Exp. Ther. 278 1996 1146-1152
39. J.U. Scher M.H. Pillinger 15d-PGJ2: The anti-inflammatory prostaglandin? Clin. Immunol. 114 2005 100-109
40. 2, attenuates the development of cyclophosphamide induced cystitis in the rat J. Urol. 171 2004 500